A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET).

Authors: Susumu Hijioka, Yoshitaka Honma, Nozomu Machida, Nobumasa Mizuno, Tetsuya Hamaguchi, Narikazu Boku, Ryo Sadachi, Nobuyoshi Hiraoka, Takuji Okusaka, Hidekazu Hirano, Shogen Boku, Masafumi Ikeda, Satoshi Takeuchi, Noriyoshi Fukushima, Motohiro Kojima, Noriko Mitome, Yusuke Sano, Takaki Yoshikawa, Yukihide Kanemitsu, Makoto Ueno,

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.652

Source: Full article

---

Abstract

652